Our aim was to slow down blood clearance, increase delivery to the tumors, and, consequently, enhance the anticancer efficacy of systemically administered HER2-retargeted ReHV by combining the decrease in gC-mediated binding to GAGs with the specific retargeting to cancer receptors intrinsic to ReHV technology. This evidence concerns the gene ERBB2 and cancer.